Novo Nordisk's Pipeline Wins and Buyback Ledger Can't Answer the Ozempic Question
Published on 10/26/2026 at 16:32 | Editorial boerse-global.de
Novo Nordisk has spent the past few weeks stacking up announcements — a pediatric approval, subgroup data on an experimental obesity drug, and a steady drip of share repurchases. None of them settles the issue that has been weighing on the stock: what happens to Ozempic in the United States.
A Trimmed Target and a Tough Comparison
On 12 October, BMO Capital cut its price target on Novo Nordisk to $40 from $47, keeping a "Market Perform" rating. Analyst Evan Seigerman pointed to expected headwinds for Ozempic in the US. Layered on top is a favorable gross-to-net effect from the prior year, which should make the decline in US Ozempic sales in the third quarter of 2026 look steeper year over year.
That distinction matters for investors: an unfavorable base effect is not the same thing as operational deterioration. Seigerman's view is a forecast, not a reported quarterly result.
Buybacks: A Framework, Not a Finished Job
Separately, Novo Nordisk is leaning on share repurchases alongside its drug progress. A mandatory disclosure filed on 19 October documents the rollout of the existing program, which authorizes up to DKK 15 billion over twelve months starting 4 February 2026. That ceiling describes the intended framework, not a completed buyback.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The distinction is worth keeping straight — an authorization and its actual use are different things, and the filing makes the implementation status transparent without announcing any expansion of the program. As of 16 October, Novo Nordisk had repurchased a total of 39,074,179 B shares for DKK 10,875,024,304, according to the notice filed with the US Securities and Exchange Commission.
So alongside the product news sits a concrete capital measure. Its informational value is limited, though: the documented share purchases say nothing about how revenue and earnings are developing.
What the Product News Actually Shows
The FDA has approved Awiqli, a once-weekly basal insulin, to improve blood sugar control in children aged ten and older with type 2 diabetes. According to the company, it is the first and only once-weekly insulin for this patient group. That is a genuine regulatory step — but it is not proof of additional revenue, nor does it offer any relief for the US Ozempic business.
A different kind of announcement came roughly a week earlier, when Novo Nordisk reported post-hoc analyses of the REDEFINE 1 trial. Among women with overweight or obesity, the investigational drug CagriSema was associated with an average weight loss of 25.0% after 68 weeks, versus 3.0% on placebo. The figures assumed patients adhered to treatment, and the analyses covered women at various stages of menopause. Both the post-hoc nature of the work and CagriSema's status as an investigational compound remain central to how the data should be read. The results were presented at the annual meeting of the Menopause Society.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The Date That Matters
Novo Nordisk has scheduled publication of its results for the first nine months of 2026 for 4 November. That report is the next concrete checkpoint for testing expectations against reported figures, and it will round out the product announcements and the documented buyback status with actual business numbers.
Until then, the takeaway is one of separate ledgers: Awiqli represents a regulatory win, CagriSema clinical potential, and the buyback a record of capital deployment. Whether — and how severely — the feared Ozempic pressures show up in the ongoing business is a question only the financial statements can answer.
Ad
Novo Nordisk Stock: New Analysis - 26 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
